Catalyst Pharmaceutical CPRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Agamree | $36.71M+66.6% | $35.3M+67.5% | $32.38M+115% | $27.36M+213% | $22.04M+1,778% | |
| Firdapse | $98.86M+18.1% | $97.62M+18.3% | $92.18M+16.2% | $84.85M+9.7% | $83.73M+25.3% | |
| Fycompa | $13.77M-61.3% | $19.58M-48.8% | $23.8M-25.8% | $34.33M-6.0% | $35.63M+17.1% | |
| Product Revenue Net | $149.34M+5.6% | $152.5M+7.5% | $148.37M+17.4% | $146.54M+19.5% | $141.4M+43.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Catalyst Pharmaceutical break its business down?
- Catalyst Pharmaceutical (CPRX) reports revenue by product across 4 parts — Agamree, Firdapse, Fycompa and Product Revenue Net. Each is extracted from the segment footnotes and tracked over time.
- Where does Catalyst Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Catalyst Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
